Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01803711 · ClinicalTrials.gov registry record · Phase 2
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
A Phase 2 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01803711: Clinical Trial Phase 2 study, sponsored by UConn Health.
NCT01803711 is a Phase 2 study that was terminated before completion, run by UConn Health. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01803711, a Phase 2 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions (cancer, cardiovascular diseases and diabetes).
Primary Outcome
Hospital Anxiety and Depression Scale: This is a validated scale for measuring depression/anxiety symptoms in patients with medical conditions.
Interventions
- DRUG Desvenlafaxine
- DIETARY_SUPPLEMENT Omega 3 Fatty acids
- DRUG Placebo (for Omega 3 fatty acid supplement)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Why NCT01803711 stopped before completion
NCT01803711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which Desvenlafaxine is the first listed.
NCT01803711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01803711 about?
NCT01803711 is a clinical study titled "Omega 3 FA Supplements as Augmentation in the Treatment of Depression". To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions (cancer, cardiovascular diseases and diabetes).
What is the current status of trial NCT01803711?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2013-02. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01803711?
The interventions under investigation include: Desvenlafaxine (DRUG), Omega 3 Fatty acids (DIETARY_SUPPLEMENT), Placebo (for Omega 3 fatty acid supplement) (DRUG).
Who is sponsoring clinical trial NCT01803711?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01803711's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia